Efficacy of lyophilized Lactobacillus sakei as a potential candidate for preventing carbapenem-resistant Klebsiella infection DOI Creative Commons
Hanieh Tajdozian, Hoonhee Seo,

Yoonkyoung Jeong

et al.

Annals of Microbiology, Journal Year: 2024, Volume and Issue: 74(1)

Published: Aug. 9, 2024

Abstract Background Antimicrobial resistance is considered one of the greatest threats to human health, according World Health Organization (WHO). Gram-negative bacteria, especially carbapenem-resistant Enterobacteriaceae (CRE), have become a significant concern in antimicrobial-resistant bacteria’s global emergence and spread. Among CRE pathogens, Klebsiella pneumoniae (CRKP) has recently been reported as highly infectious strain associated with high mortality morbidity adults immunocompromised patients. Additionally, CRKP-related infections are challenging treat, carbapenems last resort antibiotics. Therefore, developing novel drugs different mechanisms action from existing urgently required defeat this lethal menace. Under such circumstances, probiotics can be therapeutic candidates for inhibiting pathogens. Thus, our research team focusing on long time develop potential anti-CRKP drug agents. Methods After extensive efforts, we finally found probiotic strain, Lactobacillus sakei PMC104, suitable treating CRKP infection. It was isolated kimchi. As part expansion into development, evaluated L. effect against pathogens both vitro vivo experiments. Moreover, conducted media optimization at food grade then established scale-up process pilot scale. Subsequently, lyophilizate obtained used mouse model infected CRKP. Results Data demonstrated that an inhibitory infection experiments also increases level short-chain fatty acids feces mice after receiving treatment 10 days. Furthermore, powder remarkably diminished body weight loss, mortality, illness severity CRKP-infected mice, showing preventive PMC 104 Discussion Our results demonstrate candidate CRKP, suggesting could antimicrobial infections. However, studies, including additional toxicity tests clinical trials, still essential it new agent.

Language: Английский

The Role of Artificial Intelligence and Machine Learning in Predicting and Combating Antimicrobial Resistance DOI Creative Commons
Hazrat Bilal, Muhammad Nadeem Khan, Sabir Khan

et al.

Computational and Structural Biotechnology Journal, Journal Year: 2025, Volume and Issue: 27, P. 423 - 439

Published: Jan. 1, 2025

Antimicrobial resistance (AMR) is a major threat to global public health. The current review synthesizes address the possible role of Artificial Intelligence and Machine Learning (AI/ML) in mitigating AMR. Supervised learning, unsupervised deep reinforcement natural language processing are some main tools used this domain. AI/ML models can use various data sources, such as clinical information, genomic sequences, microbiome insights, epidemiological for predicting AMR outbreaks. Although relatively new fields, numerous case studies offer substantial evidence their successful application outbreaks with greater accuracy. These provide insights into discovery novel antimicrobials, repurposing existing drugs, combination therapy through analysis molecular structures. In addition, AI-based decision support systems real-time guide healthcare professionals improve prescribing antibiotics. also outlines how AI surveillance, analyze trends, enable early outbreak identification. Challenges, ethical considerations, privacy, model biases exist, however, continuous development methodologies enables play significant combating

Language: Английский

Citations

5
N-of-1 medicine DOI Open Access
Peter Wang, Qiao Ying Leong, Ni Yin Lau

et al.

Singapore Medical Journal, Journal Year: 2024, Volume and Issue: 65(3), P. 167 - 175

Published: March 1, 2024

Abstract The fields of precision and personalised medicine have led to promising advances in tailoring treatment individual patients. Examples include genome/molecular alteration-guided drug selection, single-patient gene therapy design synergy-based combination development, these approaches can yield substantially diverse recommendations. Therefore, it is important define each domain delineate their commonalities differences an effort develop novel clinical trial designs, streamline workflow rethink regulatory considerations, create value healthcare economics assessments, other factors. These segments are essential recognise the diversity within domains accelerate respective workflows towards practice-changing healthcare. To emphasise points, this article elaborates on concept digital health medicine-enabled N-of-1 medicine, which individualises regimen dosing using a patient’s own data. We will conclude with recommendations for consideration when developing based emerging digital-based platforms.

Language: Английский

Citations

4
Flash optimization of drug combinations for Acinetobacter baumannii with IDentif.AI-AMR DOI Creative Commons
Kui You,

Nurhidayah Binte Mohamed Yazid,

Li Ming Chong

et al.

npj Antimicrobials and Resistance, Journal Year: 2025, Volume and Issue: 3(1)

Published: Feb. 21, 2025

Abstract Antimicrobial resistance (AMR) is an emerging threat to global public health. Specifically, Acinetobacter baumannii ( A. ), one of the main pathogens driving rise nosocomial infections, a Gram-negative bacillus that displays intrinsic mechanisms and can also develop by acquiring AMR genes from other bacteria. More importantly, it resistant nearly 90% standard care (SOC) antimicrobial treatments, resulting in unsatisfactory clinical outcomes high infection-associated mortality rate over 30%. Currently, there growing challenge sustainably novel antimicrobials this ever-expanding arms race against AMR. Therefore, sustainable workflow properly manages healthcare resources ultra-rapidly design optimal drug combinations for effective treatment needed. In study, IDentif.AI-AMR platform was harnessed pinpoint regimens four isolates pool nine US FDA-approved drugs. Notably, IDentif.AI-pinpointed ampicillin-sulbactam/cefiderocol cefiderocol/polymyxin B/rifampicin were able achieve 93.89 ± 5.95% 92.23 11.89% inhibition bacteria, respectively, they may diversify reservoir options indication. addition, polymyxin B combination with rifampicin exhibited broadly applicable efficacy strong synergy across all tested isolates, representing potential strategy . potentially serve as alternative strategies

Language: Английский

Citations

0
3D Bioprinting and Artificial Intelligence‐Assisted Biofabrication of Personalized Oral Soft Tissue Constructs DOI Open Access
Yichen Dai, Peter Wang, Apurva Mishra

et al.

Advanced Healthcare Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Dec. 17, 2024

Abstract Regeneration of oral soft tissue defects, including mucogingival defects associated with the recession or loss gingival and/or mucosal tissues around teeth and implants, is crucial for restoring form, function, health. This study presents a novel approach using three‐dimensional (3D) bioprinting to fabricate individualized grafts precise size, shape, layer‐by‐layer cellular organization. A multicomponent polysaccharide/fibrinogen‐based bioink developed, parameters are optimized create shape‐controlled (gingival) constructs. Rheological, printability, shape‐fidelity assays, demonstrated influence thickener concentration print on resolution shape fidelity. Artificial intelligence (AI)‐derived tool enabled streamline iterative parameter optimization analysis interaction between parameters. The cell‐laden bioinks exhibited excellent viability fidelity shape‐controlled, full‐thickness constructs over 18‐day culture period. While variations in concentrations within minimally impact organization morphogenesis (gingival epithelial, connective tissue, basement membrane markers), they bioprinted represents significant step toward biofabrication personalized grafts, offering potential applications repair regeneration periodontal disease dental implants.

Language: Английский

Citations

2
Efficacy of lyophilized Lactobacillus sakei as a potential candidate for preventing carbapenem-resistant Klebsiella infection DOI Creative Commons
Hanieh Tajdozian, Hoonhee Seo,

Yoonkyoung Jeong

et al.

Annals of Microbiology, Journal Year: 2024, Volume and Issue: 74(1)

Published: Aug. 9, 2024

Abstract Background Antimicrobial resistance is considered one of the greatest threats to human health, according World Health Organization (WHO). Gram-negative bacteria, especially carbapenem-resistant Enterobacteriaceae (CRE), have become a significant concern in antimicrobial-resistant bacteria’s global emergence and spread. Among CRE pathogens, Klebsiella pneumoniae (CRKP) has recently been reported as highly infectious strain associated with high mortality morbidity adults immunocompromised patients. Additionally, CRKP-related infections are challenging treat, carbapenems last resort antibiotics. Therefore, developing novel drugs different mechanisms action from existing urgently required defeat this lethal menace. Under such circumstances, probiotics can be therapeutic candidates for inhibiting pathogens. Thus, our research team focusing on long time develop potential anti-CRKP drug agents. Methods After extensive efforts, we finally found probiotic strain, Lactobacillus sakei PMC104, suitable treating CRKP infection. It was isolated kimchi. As part expansion into development, evaluated L. effect against pathogens both vitro vivo experiments. Moreover, conducted media optimization at food grade then established scale-up process pilot scale. Subsequently, lyophilizate obtained used mouse model infected CRKP. Results Data demonstrated that an inhibitory infection experiments also increases level short-chain fatty acids feces mice after receiving treatment 10 days. Furthermore, powder remarkably diminished body weight loss, mortality, illness severity CRKP-infected mice, showing preventive PMC 104 Discussion Our results demonstrate candidate CRKP, suggesting could antimicrobial infections. However, studies, including additional toxicity tests clinical trials, still essential it new agent.

Language: Английский

Citations

1